REGENXBIO is leveraging its proprietary NAV® Technology and collaborating with world-class clinical advisors to advance the development of life-changing gene therapy treatments for lysosomal storage disorders and ocular diseases.
REGENXBIO to Present at Upcoming Investor Conferences Wed, 22 Nov 2017 12:00:00 +0000 ROCKVILLE, Md., Nov. 22, 2017-- REGENXBIO Inc., a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology ...
Regenxbio reports 3Q loss Wed, 08 Nov 2017 22:33:58 +0000 The Rockville, Maryland-based company said it had a loss of 67 cents per share. The biotechnology company posted revenue of $1.3 million in the period. Regenxbio shares have climbed 42 percent since the ...
REGENXBIO, Inc. breached its 50 day moving average in a Bearish Manner : RGNX-US : November 2, 2017 Thu, 02 Nov 2017 12:31:01 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for REGENXBIO, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more
(Read more...)
ETFs with exposure to REGENXBIO, Inc. : October 30, 2017 Mon, 30 Oct 2017 16:12:44 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to REGENXBIO, Inc. Here are 5 ETFs with the largest exposure to RGNX-US. Comparing the performance and risk of REGENXBIO, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
(Read more...)
Gene Therapies: A Foot in the Door Fri, 13 Oct 2017 16:31:00 +0000 The yes vote by the FDA advisory panel for Spark Therapeutics’ (ONCE) drug Luxturna has opened the door for gene therapies at the FDA. Leerink’s Joseph Schwartz weighed in on that very topic today. Proclaiming it “a new era for gene therapy,” he says the results of yesterday’s vote is a “momentous advance” for the drug category that suggests that the public’s and regulators’ long-standing caution is “at an inflection point.” If the FDA follows-through on today's unanimous vote and approves Luxturna by Jan 12, 2018, we believe the tailwind could benefit companies like Audentes (BOLD [OP]), BioMarin (BMRN [OP]), REGENXBIO (RGNX [NR]), uniQure (QURE [OP]) and Ultragenyx (RARE [OP]) post-DMTX acquisition.
REGENXBIO, Inc. :RGNX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 Fri, 06 Oct 2017 13:09:07 +0000 Categories: Yahoo FinanceGet free summary analysis REGENXBIO, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 6.56 million, Net Earnings of USD -14.47 million. Gross margins widened from 79.03% to 79.93% compared to the same period last year, operating (EBITDA) margins now -218.73% from -628.04%. Change in operating cash ... Read more
(Read more...)
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.
Accum/Dist: 1.70 (median winner: 1.53)
Above 40wkMA: 31% (median winner: 35%)
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.